WHO ICTRP trial
A multicenter randomized phase II clinical trial with neo -adjuvant chemotherapy…
JPRN-UMIN000023162 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000023162 |
|---|---|
| Public title | A multicenter randomized phase II clinical trial with neo -adjuvant chemotherapy containing eribulin mesylate for triple negative primary breast cancer patients (Neo-Entrance study) |
| Scientific title | A multicenter randomized phase II clinical trial with neo -adjuvant chemotherapy containing eribulin mesylate for triple negative primary breast cancer patients (Neo-Entrance study) - A multicenter randomized phase II clinical trial with neo -adjuvant chemotherapy containing eribulin mesylate for… |
| Primary sponsor | Japan Breast Cancer Research Group) |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase II |
| Countries | Japan |
| Conditions | Patients with operable primary triple-negative breast cancer without prior treatment |
| Interventions | Group A-1 Patient "with age <65 years and HRD positive" or "with BRCA mutation" 1)Combination therapy (paclitaxel + carboplatin) 4 cycles ,2)FEC or AC therapy (4 cycles) ,3) surgery Combination therapy Cycles 1-4: paclitaxel at mg/m2 once… |
| Registration date | Sep 15, 2016 |
| Target size | 200 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: